Moderna cuts high end of 2025 revenue outlook on vaccine shipment delay in U.K.
-
最新报道：Moderna reported Q2 2025 earnings of $3.2 billion, beating analyst estimates, driven by strong global demand for its mRNA-based vaccines and therapeutics. The biotech firm also raised its full-year revenue guidance to $12.5-$13 billion, citing expanded manufacturing capacity and new product launches. CEO Stéphane Bancel highlighted progress in late-stage trials for cancer and rare disease treatments, with regulatory submissions expected in early 2026. Shares rose 7% in pre-market trading following the earnings release.
下一篇
US Congressman Sounds Alarm as Tokenization Redefines Public and Private Companies
- Tokenized stocks are gaining traction in the Web3 space, allowing investors to trade share...
24小时热点
热点专题
407106